Major pitfall identified in popular prostate cancer PET imaging method

Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging has become a popular method for determining the stage of a patient's prostate cancer. However, researchers have identified a major pitfall in this imaging technique and are cautioning medical professionals to be aware of the potential for misdiagnosis when relying solely on PSMA PET. The study is featured in The Journal of Nuclear Medicine's September issue.

PSMA is a highly expressive enzyme in prostate cancer cells and metastases, which makes it a very useful target for imaging, allowing physicians to more easily diagnose the cancer and determine best treatments. However, past studies have noted that some benign tissues also show increased PSMA expression and could potentially be confused with lymph node metastases. These tissues include parts of the kidney, bowels, salivary glands and ganglia along the sympathetic trunk. The result could be a misdiagnosis and unnecessary change in therapy regimen.

"It is important that nuclear medicine physicians be aware of this pitfall, as the interpretation of PSMA PET scans may have a substantial impact on therapy guidance," said Christoph Rischpler, MD, in the department of nuclear medicine at the Technical University of Munich in Germany.

The study focused on PSMA-ligand uptake in cervical, coeliac and sacral ganglia. The researchers analyzed 407 patients and compared the findings to adjacent lymph node metastases. They found that the uptake was above background levels in 401 patients, or 98.5 percent of participants.

Despite these findings, the researchers urge medical professionals not to completely abandon PSMA PET imaging. Instead, they suggest, nuclear medicine physicians should analyze PSMA-ligand uptake in conjunction with exact localization and configuration of the respective lesion to differentiate expressive ganglia from lymph node metastases and to avoid misinterpretation.

Rischpler stated, "We hope that an increased awareness among nuclear medicine physicians of this important pitfall helps to increase diagnostic accuracy and improve therapy guidance, preventing unnecessary procedures for prostate cancer patients."

Source: http://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=29956

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Assessing the impact of gozetotide in PSMA-positive prostate cancer